GlassScriptPhysician profile
Beatriz Blinov
NPI 1922456573
$1,892.29
in general payments reported to CMS, 2019-2025
17 companies · $53.88 in 2025
The $53.88 reported for 2025 was less than what a typical Pediatric Endocrinology provider received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $177 · 2023: $1,138 · 2024: $524 · 2025: $53.88.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,715.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,715.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $414.72 | 2022-2025 | Sogroya, Norditropin |
| Ascendis Pharma Endocrinology INC | $269.21 | 2022-2024 | |
| Kyowa Kirin, INC. | $207.74 | 2023-2024 | Crysvita |
| Abbvie INC. | $194.29 | 2022-2024 | Lupron Depot |
| Abbott Laboratories | $160.14 | 2023-2024 | Freestyle Libre |
| Tolmar, INC. | $142.83 | 2023-2025 | Fensolvi |
| Biomarin Pharmaceutical INC. | $126.11 | 2023-2024 | Voxzogo 1.2mg |
| Insulet Corporation | $109.13 | 2022-2024 | Omnipod |
| Xeris Pharmaceuticals, INC. | $61.02 | 2022-2023 | Gvoke Hypopen |
| Dexcom, INC. | $54.91 | 2023-2024 | Dexcom G6 Transmitter |
| Eton Pharmaceuticals, INC. | $46.66 | 2023-2024 | Alkindi |
| Tandem Diabetes Care, INC. | $22.17 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Pfizer INC. | $21.02 | 2024 | |
| Beta Bionics, INC. | $18.17 | 2024 | Ilet Bionic Pancreas |
| Azurity Pharmaceuticals, INC. | $16.45 | 2023 | Triptodur |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $14.99 | 2023 | |
| Ibsa Pharma INC. | $12.73 | 2023 | Tirosint, Licart |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beatriz Blinov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.